Mooncast (Montelukast)

Montelukast, the active ingredient in Mooncast, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It works by blocking cysteinyl leukotriene receptors in the airways, reducing inflammation and bronchoconstriction, and is indicated for the management of asthma, exercise‑induced bronchoconstriction, and allergic rhinitis in adults and children.

GNH USA supplies Mooncast as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU regulatory standards and is manufactured under GMP conditions.

Montelukast acts on leukotriene pathways to control airway inflammation and allergic symptoms.

- Asthma: improves control of chronic airway inflammation and reduces frequency of exacerbations. - Exercise‑induced bronchoconstriction: prevents narrowing of airways triggered by physical activity. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching caused by allergic inflammation.

Montelukast may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate pain in the head. - Abdominal pain: discomfort or cramps in the stomach area. - Cough: transient irritation of the respiratory tract. - Nausea: feeling of queasiness or urge to vomit. - Diarrhea: loose, watery stools. - Fatigue: general sense of tiredness.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue or throat. - Stevens‑Johnson syndrome: severe skin rash with blistering. - Hepatic injury: elevated liver enzymes or jaundice. - Neuropsychiatric events: mood changes, depression or suicidal thoughts. - Anaphylaxis: rapid, life‑threatening allergic reaction.

When prescribing Montelukast, clinicians should consider several safety and handling measures.

- Assess liver function: evaluate hepatic status before initiating therapy. - Monitor neuropsychiatric symptoms: watch for mood changes, depression or suicidal ideation. - Use caution in severe hepatic impairment: dose adjustment may be required. - Avoid in patients with known hypersensitivity to Montelukast or any tablet excipients. - Review concomitant medications: consider potential drug interactions. - Store at room temperature: keep in the original container, protect from moisture and light.

Montelukast can interact with other medicines, altering its plasma concentration or therapeutic effect.

Major Interactions (Avoid): - Ritonavir: strong CYP3A4 inhibition can markedly increase Montelukast levels. - Phenobarbital: potent CYP3A4 induction may reduce Montelukast exposure. - Ketoconazole: significant CYP3A4 inhibition may raise drug concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: possible effect on INR; monitor coagulation parameters. - Beta‑agonists (e.g., albuterol): additive bronchodilation may enhance respiratory effects. - Theophylline: monitor for altered plasma levels and potential toxicity.